Abstract
Charles S. Fuchs, MD, MPH; Levi A. Garraway, MD, PhD; and Laurie H. Glimcher, MD, are featured.
Charles S. Fuchs, MD, MPH, became director and physician-in-chief of Yale Cancer Center and Smilow Cancer Hospital in New Haven, CT, on January 1. He replaces Thomas J. Lynch Jr., MD. Previously, Fuchs directed the Center for Gastrointestinal Cancer at Dana-Farber Cancer Institute (DFCI) in Boston, MA. In addition to his clinical work, Fuchs pursued laboratory research, studying markers of gastrointestinal cancer risk, molecular predictors of prognosis in colorectal and pancreatic cancers, and novel therapeutic targets.
Levi A. Garraway, MD, PhD, joined Eli Lilly and Company as senior vice president of Global Oncology, succeeding Richard Gaynor, MD, on January 1. A world leader in the analysis of cancer genomics and resistance to targeted therapies, Garraway previously directed the Joint Center for Cancer Precision Medicine, which includes DFCI, Brigham and Women's Hospital, and Boston Children's Hospital, as well as the Broad Institute of MIT and Harvard in Cambridge, MA. In addition, he co-led the Cancer Genetics Program at the Dana-Farber/Harvard Cancer Center.
Also on January 1, Laurie H. Glimcher, MD, began her new role as president and CEO of DFCI, succeeding Edward J. Benz Jr., MD. She will also serve as president of Dana-Farber/Partners Cancer Center. Formerly, Glimcher worked as the dean of the medical college at Weill Cornell Medicine in New York, NY, and as provost for Medical Affairs at Cornell University. An internationally recognized immunologist with a deep understanding of differentiation pathways in lymphocytes, she has made seminal discoveries of key transcription factors that drive lineage commitment and activation in the immune system.
For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.
